← Human Trials & Peer-Reviewed Studies
Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype
Plain-language guide to PMID 18779512 (2008): single-blind controlled clinical trial study of CGRP (Calcitonin Gene-Related Peptide) in 9 patients, migraine.
Key Facts
- PMID
- 18779512
- Journal
- Neurology
- Year
- 2008
- Study type
- Controlled Clinical Trial
- Authors
- Hansen JM et al. (4 authors)
- DOI
- 10.1212/01.wnl.0000325482.64106.3f
What This Study Did, in Plain Language
What Was Tested
Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this controlled clinical trial publication.
The neuropeptide calcitonin gene-related peptide (CGRP) is a migraine trigger that plays a crucial role in migraine pathophysiology, and CGRP antagonism is efficient in the treatment of migraine attacks.
FHM shares many phenotypical similarities with common types of migraine, indicating common neurobiological pathways.
The researchers tested the hypothesis that the FHM genotype confers a CGRP hypersensitive phenotype.
Who Took Part
The study group was 9 patients.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
The researchers included 9 FHM patients with known mutations in the CACNA1A and ATP1A2 genes and 10 healthy controls.
How the Study Was Run
The design is described as single-blind.
Only one side, usually the patients, was kept unaware of whether CGRP (Calcitonin Gene-Related Peptide) was given.
The researchers recorded headache intensity on a verbal rating scale and vascular changes in the middle cerebral artery and the superficial temporal artery.
What Was Measured
PubMed files the paper under topics including Blood Flow Velocity, Calcitonin Gene-Related Peptide, Cyclic AMP, Migraine with Aura, Mutation, Phenotype and Signal Transduction.
What This Means in Plain Language
The paper is a single-blind study of CGRP (Calcitonin Gene-Related Peptide) in 9 patients in people with migraine.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2008 (Neurology), a journal based in United States.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.